Initial Management of Rheumatoid Arthritis

Rheumatic Disease Clinics of North America

Volumn 38, Issue 2, 2012, Pages 311-325

  Gramling, Anna ^a,b   O'Dell, James R ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Disease modifying antirheumatic drug; DMARD; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; EARLY DIAGNOSIS; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PROGNOSIS; REMISSION INDUCTION; TIME FACTORS;

EID: 84863997412     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.05.003     Document Type: Review

References (106)

1. Smolen J.S., van der Heijde D.M., Aletaha D., et al. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 2009, 68(10):1535-1540.
2. Sokka T., Kautiainen H., Mottonen T., et al. Erosions develop rarely in joints without clinically detectable inflammation in patients with early rheumatoid arthritis. J Rheumatol 2003, 30(12):2580-2584.
3. Aletaha D., Funovits J., Smolen J.S. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis 2011, 70(5):733-739.
4. Smolen J.S., Aletaha D., Grisar J.C., et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010, 69(6):1058-1064.
5. van der Heijde D., Landewe R., van Vollenhoven R., et al. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008, 67(9):1267-1270.
6. Drossaers-Bakker K.W., de Buck M., van Zeben D., et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999, 42(9):1854-1860.
7. Finckh A., Liang M.H., van Herckenrode C.M., et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006, 55(6):864-872.
8. Kyburz D., Gabay C., Michel B.A., et al. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford) 2011, 50(6):1106-1110.
9. Anderson J.J., Wells G., Verhoeven A.C., et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000, 43(1):22-29.
10. Nell V.P., Machold K.P., Eberl G., et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004, 43(7):906-914.
11. Garnero P., Thompson E., Woodworth T., et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010, 62(1):33-43.
12. Heiberg M.S., Rodevand E., Mikkelsen K., et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study. Ann Rheum Dis 2006, 65(10):1379-1383.
13. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41(9):1552-1563.
14. Smolen J.S. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol Suppl 1999, 112:15-21.
15. Takeuchi T., Tanaka Y., Amano K., et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology (Oxford) 2011, 50(10):1908-1915.
16. Tanaka Y., Harigai M., Takeuchi T., et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012, 71(6):817-824.
17. O'Dell J.R., Haire C.E., Erikson N., et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334(20):1287-1291.
18. Mottonen T., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999, 353(9164):1568-1573.
19. Korpela M., Laasonen L., Hannonen P., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004, 50(7):2072-2081.
20. Rantalaiho V., Korpela M., Laasonen L., et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010, 12(3):R122.
21. Boers M., Verhoeven A.C., Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350(9074):309-318.
22. Landewe R.B., Boers M., Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002, 46(2):347-356.
23. van Tuyl L.H., Boers M., Lems W.F., et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010, 69(5):807-812.
24. Bosello S., Fedele A.L., Peluso G., et al. Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 2011, 70(7):1292-1295.
25. Aletaha D., Neogi T., Silman A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581.
26. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
27. Harrison B.J., Symmons D.P., Barrett E.M., et al. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol 1998, 25(12):2324-2330.
28. Cader M.Z., Filer A., Hazlehurst J., et al. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 2011, 70(6):949-955.
29. Kaneko Y., Kuwana M., Kameda H., et al. Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2011, 50(7):1268-1274.
30. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50(2):380-386.
31. van der Woude D., Rantapaa-Dahlqvist S., Ioan-Facsinay A., et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010, 69(8):1554-1561.
32. van de Stadt L.A., de Koning M.H., van de Stadt R.J., et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011, 63(11):3226-3233.
33. Koivula M.K., Heliovaara M., Ramberg J., et al. Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Ann Rheum Dis 2007, 66(11):1450-1455.
34. Bos W.H., Wolbink G.J., Boers M., et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010, 69(3):490-494.
35. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48(10):2741-2749.
36. Chibnik L.B., Mandl L.A., Costenbader K.H., et al. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 2009, 36(4):706-711.
37. Shadick N.A., Cook N.R., Karlson E.W., et al. C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med 2006, 166(22):2490-2494.
38. Nishimura K., Sugiyama D., Kogata Y., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146(11):797-808.
39. Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43(1):155-163.
40. van Gaalen F.A., van Aken J., Huizinga T.W., et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004, 50(7):2113-2121.
41. Bas S., Perneger T.V., Seitz M., et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002, 41(7):809-814.
42. Goldbach-Mansky R., Lee J., McCoy A., et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000, 2(3):236-243.
43. Kroot E.J., de Jong B.A., van Leeuwen M.A., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43(8):1831-1835.
44. van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004, 50(3):709-715.
45. Bykerk V.P. Strategies to prevent rheumatoid arthritis in high-risk patients. Curr Opin Rheumatol 2011, 23(2):179-184.
46. Deane K.D., Norris J.M., Holers V.M. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am 2010, 36(2):213-241.
47. Gerlag D.M., Raza K., van Baarsen L.G., et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk factors for Rheumatoid Arthritis. Ann Rheum Dis 2012, 71(5):638-641.
48. Kolfenbach J.R., Deane K.D., Derber L.A., et al. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum 2009, 61(12):1735-1742.
49. van de Sande M.G., de Hair M.J., van der Leij C., et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011, 70(5):772-777.
50. van der Heijde D.M., van 't Hof M., van Riel P.L., et al. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 1993, 20(3):538-541.
51. Prevoo M.L., van 't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38(1):44-48.
52. McInnes I.B., O'Dell J.R. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010, 69(11):1898-1906.
53. Smolen J.S., Breedveld F.C., Schiff M.H., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003, 42(2):244-257.
54. Aletaha D., Nell V.P., Stamm T., et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005, 7(4):R796-R806.
55. Wolfe F., Michaud K., Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005, 32(12):2410-2415.
56. Yazici Y., Bergman M., Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 2008, 35(4):603-609.
57. Soubrier M., Lukas C., Sibilia J., et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011, 70(4):611-615.
58. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364(9430):263-269.
59. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59(6):762-784.
60. Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69(6):964-975.
61. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(5):625-639.
62. ACCORD Study Group, Gerstein H.C., Miller M.E., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364(9):818-828.
63. Aletaha D., Ward M.M., Machold K.P., et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005, 52(9):2625-2636.
64. Fransen J., Creemers M.C., Van Riel P.L. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43(10):1252-1255.
65. Fransen J., van Riel P.L. DAS remission cut points. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S29-S32.
66. Smolen J.S., Aletaha D. What should be our treatment goal in rheumatoid arthritis today?. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S7-S13.
67. van der Heijde D., Klareskog L., Boers M., et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005, 64(11):1582-1587.
68. van Tuyl L.H., Vlad S.C., Felson D.T., et al. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009, 61(5):704-710.
69. Wells G.A., Boers M., Shea B., et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005, 32(10):2016-2024.
70. Felson D.T., Smolen J.S., Wells G., et al. American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63(3):573-586.
71. Vermeer M., Kuper H.H., van der Bijl A.E., et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion 2012, Rheumatology, Oxford (UK).
72. O'Dell J.R., Mikuls T.R. To improve outcomes we must define and measure them: toward defining remission in rheumatoid arthritis. Arthritis Rheum 2011, 63(3):587-589.
73. Shahouri S.H., Michaud K., Mikuls T.R., et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011, 63(11):3204-3215.
74. Block S.R. Definition of rheumatoid arthritis remission in clinical practice: comment on the article by Felson et al. Arthritis Rheum 2011, 63(11):3642. [author's reply: 3644].
75. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69(4):631-637.
76. Vermeer M., Kuper H.H., Hoekstra M., et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch rheumatoid arthritis monitoring remission induction cohort study. Arthritis Rheum 2011, 63(10):2865-2872.
77. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52(11):3381-3390.
78. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007, 146(6):406-415.
79. Kameda H., Ueki Y., Saito K., et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol 2010, 20(6):531-538.
80. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54(1):26-37.
81. Calguneri M., Pay S., Caliskaner Z., et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999, 17(6):699-704.
82. Emery P., Breedveld F.C., Hall S., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372(9636):375-382.
83. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy Study Group. N Engl J Med 2000, 343(22):1594-1602.
84. van der Heijde D., Klareskog L., Rodriguez-Valverde V., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54(4):1063-1074.
85. Kremer J.M., Russell A.S., Emery P., et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011, 70(10):1826-1830.
86. Kuriya B., Arkema E.V., Bykerk V.P., et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010, 69(7):1298-1304.
87. O'Dell J.R., Elliott J.R., Mallek J.A., et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006, 54(2):621-627.
88. Smolen J.S., Van Der Heijde D.M., St Clair E.W., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006, 54(3):702-710.
89. Moreland L.W., O'Dell J.R., Paulus H.E., et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis Rheum 2012, [Epub ahead of print].
90. van Vollenhoven R.F., Ernestam S., Geborek P., et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009, 374(9688):459-466.
91. Saevarsdottir S., Wallin H., Seddighzadeh M., et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011, 70(3):469-475.
92. Michaud K., Messer J., Choi H.K., et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003, 48(10):2750-2762.
93. Wolfe F., Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010, 12(2):R35.
94. Friedewald V.E., Ganz P., Kremer J.M., et al. AJC editor's consensus: rheumatoid arthritis and atherosclerotic cardiovascular disease. Am J Cardiol 2010, 106(3):442-447.
95. De Vera M.A., Choi H., Abrahamowicz M., et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011, 70(6):1020-1024.
96. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012, [Epub ahead of print].
97. Jick S.S., Choi H., Li L., et al. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009, 68(4):546-551.
98. Leung B.P., Sattar N., Crilly A., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170(3):1524-1530.
99. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363(9426):2015-2021.
100. Bingham C.O., Looney R.J., Deodhar A., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62(1):64-74.
101. Fomin I., Caspi D., Levy V., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006, 65(2):191-194.
102. Kobie J.J., Zheng B., Bryk P., et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 2011, 13(6):R209.
103. van Assen S., Holvast A., Benne C.A., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62(1):75-81.
104. Heijstek M.W., Ott de Bruin L.M., Borrow R., et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European league against rheumatism evidence-based recommendations. Autoimmun Rev 2011, 11(2):112-122.
105. Grossman J.M., Gordon R., Ranganath V.K., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010, 62(11):1515-1526.
106. O'Dell J.R., Mikuls T.R., Colbert R.A., et al. American College of Rheumatology clinical trial priorities and design conference. Arthritis Rheum 2011, 63:2151-2156.